µ¿±¹´ëÇб³°æÁÖº´¿ø

  • Ȩ
  • ȸ¿ø°¡ÀÔ
  • ºÒ±³È¸
  • ¸ÞÀÏ
  • »çÀÌÆ®¸Ê
LANGUAGE


Àü¹®¼¾Å;ȳ»

µ¿±¹´ëÇк´¿øÀÇ Áø·á°ú¸¦ ¾È³»ÇØ µå¸³´Ï´Ù.

  • ±âº»Á¤º¸
  • ¿¬±¸¾÷Àû
  • ÁÖ¿äȰµ¿
³í¹®
Reversible Pulmonary Hypertension in Adolescent with Left Atrial Myxoma,
(J Cardiovasc Ultrasound 2011;19(4):221-223)

A Case of Acute Myocardial Infarction Caused
by Distal Embolization of a Left Main Coronary Artery Thrombus,
(Korean Circ J 2010;40:46-49)

Effect of Valsartan on N-Terminal Pro-Brain Natriuretic Peptide in Patient With
Stable Chronic Heart Failure: Comparison With Enalapril
(Korean Circ J 2011;41:61-67)

Relationship between 24-h urine sodium/potassium ratio and central aortic systolic blood pressure in hypertensive patients.
Hypertens Res. 2017 Apr;40(4):405-410. doi: 10.1038/hr.2016.161. Epub 2016 Nov 24.

Epicardial Fat Thickness is Correlated with Vagal Hyperactivity in Patients with Neurally-Mediated Syncope.
J Cardiovasc Ultrasound. 2017 Jun;25(2):57-62. doi: 10.4250/jcu.2017.25.2.57. Epub 2017 Jun 29.

Association between Brachial-Ankle Pulse Wave Velocity and Microalbuminuria and to Predict the Risk for the Development of Microalbuminuria Using Brachial-Ankle Pulse Wave Velocity Measurement in Type 2 Diabetes Mellitus Patients.
Healthcare (Basel). 2019 Sep 26;7(4):111. doi: 10.3390/healthcare7040111.

Impact of 2018 ESC/ESH and 2017 ACC/AHA Hypertension Guidelines: Difference in Prevalence of White-Coat and Masked Hypertension.
Healthcare (Basel). 2020 May 3;8(2):122. doi: 10.3390/healthcare8020122.


Impact of Hospital Volume of Percutaneous Coronary Intervention (PCI) on In-Hospital Outcomes in Patients with Acute Myocardial Infarction: Based on the 2014 Cohort of the Korean Percutaneous Coronary Intervention (K-PCI) Registry.
Korean Circ J. 2020 Nov;50(11):1026-1036. doi: 10.4070/kcj.2020.0172.

Àú¼­

¸ñ·ÏÀ¸·Î




38067 °æ»óºÏµµ °æÁֽà µ¿´ë·Î 87(¼®À嵿 1090-1) ´ëÇ¥ÀüÈ­: 054-748-9300 ´ëÇ¥¸ÞÀÏ: gjmaster@dumc.or.kr / COPYRIGHT(C) 2013 DONGGUK UNIVERSITY MEDICAL CENTER. ALL RIGHTS RESERVED.
ÆÐ¹Ð¸® »çÀÌÆ®
ºÎ¼­È¨ÆäÀÌÁö ¹Ù·Î°¡±â

ÆäÀÌÁö ¸Ç À§·Î À̵¿